Q1 Earnings Forecast for Zura Bio Issued By Leerink Partnrs

Zura Bio Limited (NASDAQ:ZURA) – Leerink Partnrs increased their Q1 2025 earnings per share estimates for Zura Bio in a research report issued to clients and investors on Tuesday, March 25th. Leerink Partnrs analyst F. Khurshid now anticipates that the company will post earnings of ($0.13) per share for the quarter, up from their previous estimate of ($0.15). The consensus estimate for Zura Bio’s current full-year earnings is ($0.65) per share. Leerink Partnrs also issued estimates for Zura Bio’s Q2 2025 earnings at ($0.13) EPS, Q3 2025 earnings at ($0.14) EPS, Q4 2025 earnings at ($0.14) EPS, FY2025 earnings at ($0.53) EPS and FY2026 earnings at ($0.48) EPS.

Several other equities analysts have also weighed in on ZURA. Guggenheim reissued a “buy” rating and set a $15.00 price objective on shares of Zura Bio in a report on Wednesday. HC Wainwright reiterated a “neutral” rating and set a $5.00 price target on shares of Zura Bio in a research note on Tuesday, December 24th. Cantor Fitzgerald restated an “overweight” rating on shares of Zura Bio in a research note on Wednesday, December 11th. Oppenheimer reiterated an “outperform” rating and set a $19.00 target price (down previously from $20.00) on shares of Zura Bio in a research report on Wednesday. Finally, Chardan Capital lowered their price target on shares of Zura Bio from $12.00 to $10.00 and set a “buy” rating on the stock in a research report on Wednesday. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Zura Bio has a consensus rating of “Buy” and a consensus price target of $15.00.

Zura Bio Price Performance

Zura Bio stock opened at $1.36 on Friday. The firm has a 50 day moving average price of $1.47 and a 200-day moving average price of $2.75. Zura Bio has a twelve month low of $1.07 and a twelve month high of $6.35.

Zura Bio (NASDAQ:ZURA) last posted its quarterly earnings results on Tuesday, March 25th. The company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.09. The company had revenue of $0.00 million for the quarter.

Institutional Investors Weigh In On Zura Bio

Institutional investors and hedge funds have recently modified their holdings of the company. SG Americas Securities LLC grew its stake in Zura Bio by 51.6% during the fourth quarter. SG Americas Securities LLC now owns 23,005 shares of the company’s stock valued at $58,000 after acquiring an additional 7,828 shares in the last quarter. Wells Fargo & Company MN grew its position in shares of Zura Bio by 68.6% during the 4th quarter. Wells Fargo & Company MN now owns 23,053 shares of the company’s stock valued at $58,000 after purchasing an additional 9,379 shares in the last quarter. Bank of America Corp DE increased its holdings in shares of Zura Bio by 31.9% in the fourth quarter. Bank of America Corp DE now owns 41,222 shares of the company’s stock worth $103,000 after purchasing an additional 9,966 shares during the period. Rhumbline Advisers raised its position in shares of Zura Bio by 37.3% in the fourth quarter. Rhumbline Advisers now owns 37,657 shares of the company’s stock worth $94,000 after buying an additional 10,231 shares in the last quarter. Finally, American Century Companies Inc. bought a new stake in Zura Bio during the fourth quarter valued at $27,000. 61.14% of the stock is owned by hedge funds and other institutional investors.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.